services banner

Avance Publications

Avance understands itself as a think tank and publishes regularly new insights and concepts in industry relevant journals.

Recent Publications:

Villiger, R.: "How To Determine Fair License Terms: No Need For Rules Of Thumb Anymore" Les Nouvelles, September 2012.

Villiger, R.: "The effect of taxes on the value of start-ups" Journal of Business Valuation and Economic Loss Analysis, Vol. 5, Iss. 1, 2010.

Villiger, R., Bogdan, B.: "Valuation of complex license contracts" Journal of Commercial Biotechnology, Volume 15, Issue 4, October 2009.

Stephan, H., Bogdan, B., Villiger, R.: "Geringe Erfolgswahrscheinlichkeiten der Biotech-Forschung" GoingPublic Magazin, July 2009.

Villiger, R., Bogdan, B.: "Dissecting monoclonal antibody mega-deals" mAbs, Volume 1, Issue 2, April 2009.

Villiger, R., Bogdan, B.: "Pros and Cons of Licensing" Drug Discovery Today, Volume 14, Issues 5-6, March 2009.

Villiger, R., Bogdan, B.: "Deconstructing early-stage contracts" BioPharma Partnering, Winter2007/2008.

Villiger, R., Bogdan, B., Saintouil, J. P.:"Fair Deal?" BioPartnering Today 2006, Winter.

Villiger, R., Bogdan, B.:"Flexibilität hat ihren Preis." Finance 2006, November.

Villiger, R., Bogdan, B.:"Pitfalls of Valuation in Biotech." Journal of Commercial Biotechnology 2006, May.

Villiger, R.,"Valuation of American Call Options." Wilmott 2006, March.

Villiger, R., Bogdan, B.“What's Biotech really worth?" Scrip Magazine June 2005.

Villiger, R., Bogdan, B.: “Valuing Pharma R&D: The Catch-22 of DCF.” Journal of Applied Corporate Finance 2005, Spring.

Auerbach, Arnoldo, Bogdan, Fetchko, Stagljar: Drug Discovery Using Yeast as a Model System: A Functional Genomic and Proteomic View. Current Proteomics 2005, Vol. 1.

Villiger, R., Bogdan, B.: „Getting real about valuations in biotech.” Nature Biotechnology 2005, April.

Villiger, R., Bogdan, B.: „Real options are neither complicated nor irrealistic.” Drug Discovery Today 2004, June.

Villiger, R., Bogdan, B.: „How to Conquer a Lady: An Introduction to Real Options in Pharma and Biotech” Wilmott 2004, May.

Case study:

Villiger, R., Botteron, P.: „Real Options Applied to a Biotechnology Stock Exchange Transaction: The Merger of Cytos Biotechnology AG and Asklia Holding AG.” Taught at the universities of Zürich and Lausanne.





Home | About Avance | Services | ri:val | Publications | Book | Contact | Disclaimer-Terms